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Abstract: We investigated sequence-specific DNA alkylation using conjugates between the N-methylpyrrole (Py)-N-methylimidazole 
(Im) polyamide and the DNA alkylating agent, chlorambucil, or 1-(chloromethyl)-5-hydroxy-1,2-dihydro-3H-benz[e]indole (seco-CBI). 
Polyamide-chlorambucil conjugates 1–4 differed in the position at which the DNA alkylating chlorambucil moiety was bound to the Py-
Im polyamide. High-resolution denaturing polyacrylamide gel electrophoresis (PAGE) revealed that chlorambucil conjugates 1–4 
alkylated DNA at the sequences recognized by the Py-Im polyamide core moiety. Reactivity and sequence specificity were greatly 
affected by the conjugation position, which reflects the geometry of the alkylating agent in the DNA minor groove. Polyamide-seco-CBI 
conjugate 5 was synthesized to compare the efficacy of chlorambucil with that of seco-CBI as an alkylating moiety for Py-Im polyamides. 
Denaturing PAGE analysis revealed that DNA alkylation activity of polyamide-seco-CBI conjugate 5 was similar to that of polyamide-
chlorambucil conjugates 1 and 2. In contrast, the cytotoxicity of conjugate 5 was superior to that of conjugates 1–4. These results suggest 
that the seco-CBI conjugate was distinctly active in cells compared to the chlorambucil conjugates. These results may contribute to the 
development of more specific and active DNA alkylating agents. 
1. Introduction 
 
DNA targeting with small molecules has been studied for several 
decades1. DNA alkylating agents have been used as anticancer 
agents as they induce sufficient DNA damage to kill cancer cells2. 
Conjugates between small molecules and alkylating agents have 
superior DNA binding affinity to that of alkylating agents alone. 
Conjugates between distamycin A, a DNA minor groove binder, 
and nitrogen mustard DNA alkylating agents have superior DNA 
alkylating activity and cytotoxicity against cancer cells3. 
Antibiotics such as CC-1065 and duocarmycin derivatives are 
strong alkylating agents that bind to DNA4. These compounds 
alkylate at the N-3 position of adenines flanked by AT-rich 
sequences. Despite the effort that has been devoted to the 
development of DNA alkylating agents, their severe side effects 
have not been overcome. 
To address this problem, our group focused on the introduction of 
sequence specificities into DNA alkylating agents. Minor groove-
binding hairpin polyamides that contain N-methylpyrrole (Py)-N-
methylimidazole (Im) and uniquely recognize each of the four 
Watson–Crick base pairs were developed by Dervan et al5. Pairing 
of Im opposite Py targets the G–C base pair, and Py-Im targets the 
C–G base pair. Py-Py targets the T–A and A–T base pairs. It has 
been demonstrated that Py-Im hairpin polyamides that bind 
competitively to transcription regulatory sequences inhibit target 
gene expression6. We demonstrated that hybrid molecules 
consisting of duocarmycin A and Py-Im hairpin polyamides 
alkylated sequences predetermined by the recognition rules of the 
Py-Im polyamides7. Furthermore, we showed that introduction of 
a vinyl linker between the polyamides and 
cyclopropapyrroloindole (CPI) resulted in efficient alkylation of 
double-stranded DNA and improved cytotoxicity against cancer 
cells8. A more chemically stable indole linker and the synthetic 
alkylating agent 1,2,9,9a-tetrahydrocyclopropa[1,2-c]benz[1,2-
e]indol-4-one (CBI)9. were recently introduced for the design of 
sequence-specific DNA alkylating agents. This type of alkylating 
agent has superior stability, and can be synthesized to contain 
longer recognition sequences than other types of alkylating 
agents10. We have demonstrated that alkylation at the coding 
region of a template strand produces truncated mRNA11. We have 
also demonstrated that selective alkylation at the coding region of 
a template strand using Py-Im polyamides results in silencing of 
reporter genes (luciferase and GFP)12. 
Dervan et al. constructed a small library of conjugates between 
polyamides with different recognition sequences and 
chlorambucil13. One of these conjugates arrested the growth of 
several cancer cell lines. They demonstrated selective alkylation at 
the coding region of the histone h4c gene and inhibition of its 
expression, which indicates that sequence-specific DNA 
alkylating polyamides are promising gene-targeting drugs for 
cancer chemotherapy14. However, little is known about conjugates 
between the hairpin polyamide and chlorambucil. In this report, 
we present a comprehensive analysis of the DNA alkylating 
activities of hairpin polyamides conjugated with chlorambucil at 
various positions, their sequence specificities, and their effects on 
cell viability. We also compared the polyamide–chlorambucil 
conjugates to a polyamide–seco-CBI conjugate. 
 
2. Molecular Design and synthesis  
 
We designed agents in which the Py-Im polyamide was 
conjugated with chlorambucil at different positions: C-tail (1), N-
tail (2), N-tail with a β-alanine linker (3), and turn (4) (Figure 1a). 
To investigate the effect of the position of the conjugate, all Py-Im 
polyamides were designed to recognize the same sequence (Figure 
1b). The core moiety of the Py-Im polyamide recognizes the seven 
base pair sequence, 5′-WGCWGWC-3′ (W = A or T). All 
conjugates had one cationic tertiary amino group at the C-tail. 
 2 
Conjugate 4 had an (R)-α-diaminobutyric acid as a turn moiety. 
This turn moiety has more specific DNA alkylation activity than 
(R)-γ-diaminobutyric acid and has more efficient DNA alkylation 
activity than the stereochemically inversed (S)-α-diaminobutyric 
acid turn15. We also designed a Py-Im polyamide–seco-CBI 
conjugate (5) with an indole linker (Figure 1a). Conjugate 5 has 
the identical recognition sequences as other polyamide 
chlorambucil conjugates. The Py-Im polyamides were synthesized 
using Fmoc-based solid-phase synthesis16. Polyamides with amino 
group were coupled with chlorambucil to produce conjugates 1-4. 
A polyamide with carboxylic acid was coupled with indole-seco-
CBI alkylating unit to produce the conjugate 5 (schemes are 
shown in supporting information)17. All conjugates were purified 
by HPLC, and confirmed by ESI-TOF-MS or NMR.  
 
Figure 1. (a) A chemical structure of Py-Im polyamide–chlorambucil conjugates 1–4, Py-Im polyamide–seco-CBI conjugate 5. (b) Schematic representation 
of binding by polyamide at consensus seven-base-pair recognition sequence. W indicates A or T base. 
 







Figure 3. (a) Thermally induced strand cleavage of 5′-Texas Red-labeled 209 bp DNA fragments inserted ODN1 by polyamide-chlorambucil conjugates 1–
4. The concentrations of conjugates were 1000, 500, 100, 50, and 10 nM. Alkylation sites are shown in red arrows. (b) Schematic representation of the 
recognition of alkylation sites by 1-4. The arrows indicate the site of alkylation and the alkylating bases are shown in red. 
 
 
Figure 4. (a) Thermally induced strand cleavage of 5′-Texas Red-labeled 209 bp DNA fragments inserted inversed ODN1 by polyamide-chlorambucil 
conjugates 1–4. The concentrations of conjugates were 1000, 500, 100, 50, and 10 nM. Alkylation sites are shown in red arrows. (b) Schematic 
representation of the recognition of alkylation sites by 1-4. The arrows indicate the site of alkylation and the alkylating bases are shown in red.  
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3. High-resolution denaturing PAGE analysis of labeled 
DNA fragment alkylated by conjugates 1–4 
 
The sequence-selective DNA alkylation activity of chlorambucil 
conjugates 1–4 was investigated using a 5′-Texas Red-labeled 
DNA fragment and an automated DNA sequencer as described 
previously18. The 209 bp DNA fragment was prepared by 
inserting ODN1 (Figure 2), including two recognition sequences 
of the polyamides and several adenines at the 5′- and 3′-side of the 
recognition sequences. Nitrogen mustard DNA alkylating agents 
predominantly react at guanine bases such as the N7 positions; 
however, when located at the minor groove, they react mainly at 
adenine bases such as the N3 positions3. Alkylation was carried 
out at 23 °C for 18 h, followed by quenching with calf thymus 
DNA. The samples were heated at 95 °C under neutral conditions 
for 10 min. The alkylation sites were visualized by thermal 
cleavage of the DNA strand. Under these heating conditions, all 
the purine N3 alkylated sites in the DNA produced cleavage bands 
on the gel. The results of sequencing gel analysis of DNA 
fragments alkylated by conjugates 1–4 after heat treatment are 
shown in Figure 3. Figure 3 shows that DNA alkylation by 
conjugates 1, 2, and 3 occurred mainly at sites located on the 3′-
side of adenines recognized by the polyamide, 5′-
AGCAGTCAAAAA-3′ (site 2). Conjugates 1, 2, and 3 showed 
high alkylating activities at nanomolar concentrations. At the 
highest concentration of conjugate 1, all the DNA bands were 
disappeared probably because of the non-specific alkylation at 
many sites. On the other hand, slight DNA alkylation by conjugate 
4 occurred at two sites located on the 5′-side of the recognition 
sequence, 5′-AGCAGTC-3′ (sites 1 and 3). This alkylation result 
for conjugate 4 correspond with those of a previous report on 
polyamide–chlorambucil conjugates at the hairpin turn position14. 
Conjugate 4 resulted in little alkylation, even at a concentration of 
1 µM. 
To investigate alkylation of the complementary strand, we used 
conjugates 1–4 and a 209 bp DNA fragment inserted inversed 
ODN1 sequence (Figure 2). The results of sequence gel analysis 
are shown in Figure 4. Surprisingly, conjugate 1 showed efficient 
DNA alkylation at site 4 (5′-AAAAAGACTGCT-3′), whereas 
conjugates 2 and 3 only alkylated this site slightly. Conjugate 4 
did not provide distinct gel bands for any site. This indicates that 
conjugate 1 alkylates adenines in both strands adjacent to the 
recognition sequence of the Py-Im polyamide, whereas conjugates 
2–4 selectively alkylate only one strand.  
 
4. DNA alkylation activity and sites of polyamide-
chlorambucil conjugates 1–4 
 
The denaturing PAGE experiment revealed that the activity and 
site of DNA alkylation are dependent on the position of the 
conjugate between the DNA alkylating chlorambucil moiety and 
the polyamide. Conjugates at the C-tail and N-tail positions of the 
polyamide (1–3) had potent DNA alkylating activity, whereas the 
conjugate at the hairpin turn position (4) had slight DNA 
alkylating activity. In this experiment, the tail position of 
polyamides binding to the predetermined sequence was located at 
five adenine tracts. This sequence may allow efficient alkylation 
activity by the DNA alkylating agents. Moreover, the difference 
of DNA binding affinity of polyamides may also reflect the 
alkylation activity. Dervan and co-workers reported that 
polyamides with α-turn had lower affinity compared to that of 
polyamides with γ-turn19. The sequence specificity for the DNA 
alkylation site differed between conjugates. The geometry of 
chlorambucil conjugated with the hairpin polyamide determines 
whether the alkylation site will lie on the 3′-side (conjugates 1–3) 
or the 5′-side (conjugate 4). These results indicate that the 
microenvironment of the DNA minor groove to which polyamides 
bind is critical for activity and sequence specificity. Figure 5 
shows schematic representations of the DNA recognition and 
alkylation sites of conjugates 1–4.  
The conjugate at the C-tail of the polyamide (1) efficiently 
alkylated adenines on both strands two to four bases from the 
sequence recognized by the polyamide core moiety. In this 
conjugate, the chlorambucil moiety is flexibly conjugated with the 
cationic tertiary amine, which may have enabled DNA alkylation 
of adenines in both strands. 
The conjugate at the N-tail of the polyamide (2) efficiently 
alkylated adenines on the 3′-side one to three bases from the 
sequence recognized by the polyamide core moiety. Moreover, 
conjugate 2 exclusively alkylated the adenines in the 5′-AAAAA-
3′ sequence, not the adenines in the 3′-AAAAA-5′ sequence. This 
one-way direction was observed for several minor groove binder 
nitrogen mustard conjugates. For example, tallimustine (FCE-
24517) alkylates the specific sequence 5′-TTTTPuA-3′, where Pu 
= G or A3c. 
 
Figure 5.  Schematic representations of the alkylation sites of conjugates 1–4. Arrows indicate alkylation sites corresponding to the sites presented in Figure 
3 and 4. 
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Figure 6. (a) Thermally induced strand cleavage of 5′-Texas Red-labeled 
209 bp DNA fragments inserted ODN1 by polyamide-chlorambucil 
conjugates 1, 2, and polyamide-seco-CBI conjugate 5. The concentrations 
of conjugates were 1000, 500, 100, 50, and 10 nM. (b) A schematic 
representation of the alkylation sites of the polyamide-seco-CBI conjugate 
5. Arrows indicate alkylation sites corresponding to the sites presented in 
Figure 6a. 
The conjugate at the N-tail of the polyamide via a β-alanine linker 
between the polyamide and chlorambucil (3) showed the similar 
alkylating property as 2, exclusively alkylating the adenines in the 
5′-AAAAA-3′ sequence. Conjugate 3 slightly reduced activity at 
the 3′-side two to four bases from the recognition sequence 
because β-alanine acts as a one-base spacer.  
The conjugate at the (R)-α-diaminobutyric acid hairpin turn of the 
polyamide (4) slightly alkylated specific adenines on the 5′-side 
according to the sequence recognized by the hairpin turn moiety 
of the polyamide. Dervan and co-workers also demonstrated 
highly selective DNA alkylation by a polyamide–chlorambucil 
conjugate at the hairpin turn position15. Gottesfeld and co-workers 




5. DNA alkylation activity and sites of a polyamide-
seco-CBI conjugate 5 
 
There are several reports on conjugates between the Py-Im 
polyamide and alkylating agents20, but a comparison between their 
properties is lacking. Then, we examined alkylation by the 
polyamide–seco-CBI conjugate (5) and polyamide–chlorambucil 
conjugates 1 and 2 using a 5′-Texas Red-labeled 209 bp DNA 
fragment. The results of sequencing gel analysis of the alkylated 
DNA fragment after heat treatment are shown in Figure 6a. 
Conjugate 5 mainly alkylated site 3 (5′-AGCAGTCAAAAA-3′), 
corresponding with our previous results (Figure 6b). Conjugate 5 
also alkylated site d (5′-TCTTTTTAA-3′), an AT-rich sequence. 
The alkylation activity of conjugate 5 was similar to that of 
conjugate 2, indicating that both conjugates have similar 
alkylation activity. Tight binding to the DNA minor groove and a 
location of alkylating seco-CBI moiety near the adenines would 
dramatically improve DNA alkylating activity. The DNA 
alkylation sites differed slightly between conjugates.  
 
6. Cytotoxicity against a cancer cell line by conjugates 
1-5 
 
We compared the effects of the conjugates on cell viability by 
exposing human lymphocyte K562 cells to conjugates 1–5 for 48 
h. Cell viability was evaluated using the WST-8 assay. The 
concentrations of conjugates 1 and 2 in the medium containing 1% 
DMSO were limited by poor solubility to less than 2.5 µM. 
Cytotoxicity results are shown in Supporting Information. Only 
the seco-CBI conjugate (5) was severely cytotoxic at 
submicromolar concentrations. Conjugates 1 and 2 were slightly 
cytotoxic. Chlorambucil conjugate 3 was moderately cytotoxic at 
micromolar concentrations and conjugate 4 was almost nontoxic 
at a concentration of 10 µM. We were only able to estimate the 
50% growth inhibition concentrations (GI50) for conjugates 3 and 
5 (8 and 0.06 µM, respectively; Table 1). cytotoxicity against a 
cancer cell line differed significantly between the chlorambucil 
and seco-CBI conjugates. Polyamide–chlorambucil conjugates 
were cytotoxic at micromolar concentrations, whereas the 
polyamide–seco-CBI conjugate (5) was potently cytotoxic at 
submicromolar concentrations. Although DNA alkylating activity 
was similar among conjugates 1, 2, and 5 in previous experiment 
(Figure 6A), the seco-CBI conjugate 5 was over 100-fold more 
cytotoxic than the chlorambucil conjugates. This difference could 
have been caused by factors other than DNA alkylating properties 
against naked DNA fragments, such as stability of an alkylating 
moiety in an aqueous medium21, cell permeability22,or repair of 
damaged DNA23. 
 
Table 1. Estimated the 50% growth inhibition concentrations (GI50) for 
conjugates 1–5 against K562 cell. 
conjugate 1 2 3 4 5 








We investigated the DNA alkylation activity, sequence specificity, 
and cytotoxicity of Py-Im polyamides conjugated with the 
alkylating agents, chlorambucil or seco-CBI. Chlorambucil 
conjugates at the N-tail and C-tail positions had high DNA 
alkylating activities, which were similar to that of the seco-CBI 
conjugate. A chlorambucil conjugate at a turn position had low 
DNA alkylating activity, but specifically alkylated adenines 
located near the turn moiety. These results suggest that the 
geometry of alkylating agents in the DNA minor groove is 
important for alkylation activity and sequence specificity. 
Moreover, the seco-CBI conjugate is superior to chlorambucil 
conjugates with regard to the cytotoxicity in culture cells. The 
properties of an alkylating moiety are important determinants of 
the efficacy of conjugates in cells. 
Previously, we demonstrated that the substitution of one Py with 
an Im changed cytotoxicity against 39 human cancer cell lines24. 
We also demonstrated distinct differences in cytotoxicity between 
alkylating polyamides in our library25. These reports suggest that 
screening of highly active alkylating polyamides in a library is an 
alternative approach to elucidating the potential of alkylating 
polyamides. The construction of small libraries of alkylating 
polyamides with different recognition sequences and evaluation of 





Reagents and solvents were purchased from standard suppliers 
and used without further purification. Abbreviations for reagents 
are: Fmoc, fluorenylmethoxycarbonyl; Boc, tert-butoxycarbonyl; 
TFA, trifluoroacetic acid; DIEA, N,N-diisopropylethylamine; 
DMF, N,N-dimethylformamide; HCTU, 1-
[Bis(dimethylamino)methylene]-5-chloro-1H-bezotriazolium-3-
oxide hexafluorophosphate; PyBOP, benzotriazole-1-yl-oxy-tris-
pyrrolidino-phosphonium hexafluorophosphate; TIS, 
triisopropylsilane. HPLC analysis was performed with a Jasco 
PU-2080 HPLC pump, a UV-2075 HPLC UV/VIS detector, a 
Chemcobond 5-ODS-H 4.6 x 150 mm column (Chemco 
Scientific). A Chemcobond 5-ODS-H 10 x 150 mm column 
(Chemco Scientific) and a YMC-Pack Pro C18 150 x 20 mm 
column (YMC) were used in purification of polyamides. NMR 
spectra were recorded using a JEOL JNM-FX 400 nuclear 
magnetic resonance spectrometer with tetramethylsilane as 
internal standard. Proton NMR spectra were recorded in parts per 
million (ppm) downfield relative to tetramethylsilane. The 
following abbreviations apply to spin multiplicity: s (singlet), d 
(doublet), t (triplet), q (quartet), qu (quintet), m (multiplet), and br 
(broad). Electrospray ionization mass spectrometry (ESI-MS) and 
electrospray ionization time-of-flight mass spectrometry (ESI-
TOF-MS) were performed using API 150 (PE SCIEX) and 
BioTOF II (Bruker Daltonics) mass spectrometers. PCR 
amplification and DNA sequencing was carried out using the Dice 
mini thermal cycler (Takara), GoTaq Green Master Mix 
(Promega), and the Thermo Sequenase core sequencing kit (GE 
Healthcare). Loading dye was prepared with formamide and 
fuchsin red (Merck). The 5′-Texas Red-modified DNA oligomer 
(19 mer) was obtained from Sigma Genosys Co. Ltd. The 50% 
Long RangerTM gel solution was obtained from Lonza Co. Ltd. 
Polyacrylamide gel electrophoresis was performed using a 
HITACHI SQ5500-E DNA sequencer.  
 
8.2 Solid-phase synthesis of Py-Im polyamides. 
AcImPyPy-β-ImPy-γ-ImPy-β-ImPyPy-(CH2)3-NCH3-(CH2)3-
NH2 (6). All the Py-Im polyamides were synthesized in a stepwise 
reaction by Fmoc solid-phase protocol according to reported 
procedures16. Resulting AcImPyPy-β-ImPy-γ-ImPy-β-ImPyPy-
CO2-oxime resin was cleaved with 500 µL of 3,3′-diamino-N-
methyl-dipropylamine for overnight at 55 °C, and purified by 
HPLC using a YMC-Pack Pro C18 150 x 20 mm column  (H2O 
with 0.1% AcOH containing 15-35% CH3CN over a linear 
gradient for 30 min at a flow rate of 6 mL/min). The peak around 
10 min was collected and lyophilized to produce 6 (6.3 mg, 3.8 
µmol, 18%) as a yellow powder. 1H NMR (400 MHz, DMSO-d6) 
δ  10.29 (s, 2H; NH), 10.24 (s, 1H; NH), 10.22 (s, 1H; NH), 9.94 
(s, 2H; NH), 9.89 (s, 4H; NH), 8.03 (br, 4H; NH), 7.45 (s, 2H; Im-
H), 7.42 (s, 1H; Im-H), 7.41 (s, 1H; Im-H), 7.26 (s, 2H; Py-H), 
7.23 (s, 1H; Py-H), 7.21 (s, 1H; Py-H), 7.19 (s, 1H; Py-H), 7.18 (s, 
1H; Py-H), 7.17 (s, 1H; Py-H), 7.11 (s, 2H; Py-H), 6.95 (s, 1H; 
Py-H), 6.93 (s, 1H; Py-H), 6.85 (s, 1H; Py-H), 6.83 (s, 1H; Py-H), 
3.95 (s, 3H; CH3), 3.94 (s, 6H; CH3), 3.92 (s, 3H; CH3), 3.83 (s, 
6H; CH3), 3.80 (s, 6H; CH3), 3.79 (s, 6H; CH3), 3.44 (q, J=6.8 Hz, 
6H; CH2), 3.37 (q, J=6.8 Hz, 4H; CH2), 3.18 (m, 4H; CH2), 2.58 (t, 
J=6.8 Hz, 4H; CH2), 2.29 (br, 4H; CH2), 2.12 (s, 3H; CH3), 2.01 (s, 
3H; CH3), 1.82 (m, 6H; CH2), ESI-MS m/z calcd for C75H95N30O14 
[M + H]+ 1639.8; found 1639.8. 
 
NH2-ImPyPy-β-ImPy-γ-ImPy-β-ImPyPy-(CH2)3-N(CH3)2 (7). 
NH2-ImPyPy-β-ImPy-γ-ImPy-β-ImPyPy-CO2-oxime resin was 
cleaved with 500 µL of N,N′-dimethylaminopropaneamine for 
overnight at 55 °C, and purified by HPLC (the same condition as 
6) to produce 7 (11.1 mg, 7.1 µmol, 34%) as a yellow powder. 1H 
NMR (400 MHz, DMSO-d6) δ 10.29 (s, 2H; NH), 10.24 (s, 1H; 
NH), 9.98 (s, 1H; NH), 9.91 (s, 3H; NH), 9.89 (s, 2H; NH), 8.05 
(br, 4H; NH), 7.45 (s, 2H; Im-H), 7.43 (s, 2H; Im-H), 7.26 (s, 1H; 
Py-H), 7.23 (s, 1H; Py-H), 7.21 (s, 1H; Py-H), 7.20 (s, 1H; Py-H), 
7.17 (s, 2H; Py-H), 7.11 (s, 2H; Py-H), 6.95 (s, 1H; Py-H), 6.93 (s, 
1H; Py-H), 6.84 (s, 1H; Py-H), 6.82 (s, 1H; Py-H), 3.94 (s, 3H; 
CH3), 3.93 (s, 3H; CH3), 3.92 (s, 3H; CH3), 3.86 (s, 3H; CH3), 
3.83 (s, 3H; CH3), 3.81 (s, 3H; CH3), 3.80 (s, 3H; CH3), 3.79 (s, 
3H; CH3), 3.78 (s, 6H; CH3), 3.43 (q, J=6.4 Hz, 4H; CH2), 3.17 (d, 
J=5.6 Hz, 4H; CH2), 2.58 (t, J=6.8 Hz, 2H; CH2), 2.34 (t, J=7.2 
Hz, 2H; CH2), 2.23 (t, J=7.2 Hz, 2H; CH2), 2.12 (s, 6H; CH3), 
2.10 (br, 2H; CH), 1.77 (qu, J=6.8 Hz, 2H; CH2), 1.59 (qu J=6.8 
Hz, 2H; CH2); ESI-MS m/z calcd for C71H89N29O13 [M + H]+ 
1554.7; found 1554.8. 
 
NH2-β-ImPyPy-β-ImPy-γ-ImPy-β-ImPyPy-(CH2)3-N(CH3)2  
(8). A synthetic procedure similar to that used for the preparation 
of compound 7 provided 8 (11.5 mg, 7.1 µmol, 32%) as a yellow 





resin was cleaved with 500 µL of N,N′-
dimethylaminopropaneamine for overnight at 55 °C, and purified 
by HPLC (the same condition as 6), to produce Boc-protected 9. 
After deprotection Boc group with 20% TFA in dichloromethane, 
 7 
9 was obtained (9.3 mg, 5.8 µmol, 26%) as a yellow powder. ESI-
MS m/z calcd for C73H91N30O14 [M + H]+ 1611.7; found 1611.8. 
 
AcImPyPy-β-ImPy-γ -ImPy-β-Im-CO2H (10). AcImPyPy-β-
ImPy-γ-ImPy-β-Im-CO2-Wang resin was cleaved with 1 mL of 
TFA/water/TIS (95/2.5/2.5; v/v/v) for 1 h at room temperature. 
After ether precipitation, 10 was obtained (24.2 mg, 19 µmol, 
53%) as a yellow powder. 10 was used for the synthesis of 
polyamide-seco-CBI conjugate 5 without further purification. 




NH-Chlorambucil (1). To a solution of compound 6 (6.6 mg, 4.0 
µmol), PyBOP (6.1 mg, 12 µmol), and chlorambucil (4.3 mg, 14 
µmol) in DMF (100 µL), DIEA (2.4 µL, 14 µmol) was added. The 
reaction mixture was incubated overnight at room temperature. 
Evaporation of the solvent gave yellow crude, which was washed 
with ether (1 mL x 2) and dichloromethane  (1 mL x 2). HPLC 
purification was performed using a Chemcobond 5-ODS-H 10 x 
150 mm column (H2O with 0.1% AcOH containing 0-66% 
CH3CN over a linear gradient for 30 min at a flow rate of 3 
mL/min), The peak around 17 min was collected and lyophilized 
to produce conjugate 1 was obtained (2.7 mg, 1.4 µmol, 35%) as a 
white powder. 1 was used in the DNA alkylation reaction. 
Synthetic procedures were similar to that used for the preparation 
of compounds 1-4 from polyamides 6-9. 1H NMR (400 MHz, 
DMSO-d6) δ 10.38 (s, 2H; NH), 10.31 (s, 1H; NH), 10.28 (s, 1H; 
NH), 9.95 (s, 3H; NH), 9.92 (s, 1H; NH), 9.88 (s, 2H; NH), 8.08 
(br, 5H; NH), 7.44 (s, 2H; Im-H), 7.42 (s, 1H; Im-H), 7.41 (s, 1H; 
Im-H), 7.26 (s, 2H; Py-H), 7.20 (s, 1H; Py-H), 7.18 (s, 1H; Py-H), 
7.12 (s, 2H; Py-H), 6.98 (s, 1H; Py-H), 6.96 (m, 2H; benzene-H), 
6.94 (s, 1H; Py-H), 6.85 (s, 1H; Py-H), 6.83 (s, 1H; Py-H), 6.63 
(m, 2H; benzene-H), 3.93 (s, 9H; CH3), 3.92 (s, 3H; CH3), 3.83 (s, 
3H; CH3), 3.80 (s, 9H; CH3), 3.79 (s, 6H; CH3), 3.67 (m, 8H; 
CH2), 3.45 (m, 6H; CH2), 3.19 (m, 4H; CH2), 2.66 (m, 2H; CH2), 
2.58 (m, 4H; CH2), 2.32 (m, 6H; CH2), 2.11 (s, 3H; CH3), 2.01 (s, 
3H; CH3), 1.77 (m, 8H; CH2); ESI-TOF-MS m/z calcd for 
C89H112Cl2N31O15 [M + H]+ 1924.83; found 1924.96. 
 
Chlorambucil-NH-ImPyPy-β-ImPy-γ -ImPy-β-ImPyPy-
(CH2)3-N(CH3)2 (2). 2 was obtained as a white powder (1.3 mg, 
0.71 µmol, 24%) from polyamide 7. 1H NMR (400 MHz, DMSO-
d6) δ 10.28 (s, 2H; NH), 10.24 (s, 1H; NH), 10.20 (s, 1H; NH), 
9.97 (s, 1H; NH), 9.95 (s, 1H; NH), 9.90 (s, 3H; NH), 9.89 (s, 2H; 
NH), 8.06 (br, 4H; NH), 7.45 (s, 3H; Im-H), 7.42 (s, 1H; Im-H), 
7.25 (s, 2H; Py-H), 7.21 (s, 1H; Py-H), 7.19 (s, 1H; Py-H), 7.17 (s, 
2H; Py-H), 7.11 (s, 1H; Py-H), 7.02 (d, J=8.4 Hz, 2H; benzene-H), 
6.95 (s, 1H; Py-H), 6.93 (s, 1H; Py-H), 6.85 (s, 1H; Py-H), 6.82 (s, 
1H; Py-H), 6.65 (d, J=8.0 Hz, 2H; benzene-H), 3.94 (s, 3H; CH3), 
3.93 (s, 6H; CH3), 3.92 (s, 3H; CH3), 3.83 (s, 6H; CH3), 3.80 (s, 
6H; CH3), 3.79 (s, 6H; CH3), 3.68 (s, 6H; CH3), 3.43 (q, J=6.4 Hz, 
4H; CH2), 3.17 (d, J=5.6 Hz, 4H; CH2), 3.00 (br, 4H; CH2), 2.56 (t, 
J=7.2 Hz, 2H; CH2), 2.32 (t, J=8.0 Hz, 2H; CH2), 2.17 (br, 2H; 
CH2), 1.78 (m, 2H; CH2), 1.72 (m, 2H; CH2), 1.61 (m, 2H; CH2); 




(CH2)3-N(CH3)2 (3). 3 was obtained as a white powder (1.3 mg, 
0.71 µmol, 24%) from polyamide 8. ESI-TOF-MS m/z calcd for 
C88H110Cl2N31O15 [M + H]+ 1910.82; found 1910.81. 
 
AcImPyPy-β-ImPy-(R)NH-chlorambucilγ-ImPy-β-ImPyPy-(CH2)3-
N(CH3)2 (4). 4 was obtained as a white powder (3.9 mg, 2.1 µmol, 
71%) from polyamide 9. ESI-TOF-MS m/z calcd for 
C87H108Cl2N31O15 [M + H]+ 1896.80; found 1896.81. 
 
AcImPyPy-β-ImPy-γ -ImPy-β-Im-Indole-seco-CBI (5). 5 was 
synthesized according to reported procedure from polyamide 1016. 
HPLC purification was performed using a Chemcobond 5-ODS-H 
4.6 x 150 mm column (H2O with 0.1% AcOH containing 35-75% 
CH3CN over a linear gradient for 20 min at a flow rate of 1 
mL/min), The peak around 12 min was collected and lyophilized 
to produce conjugate 5 was obtained (0.5 mg, 0.3 µmol, 5%) as a 
brown powder. 5 was used in the DNA alkylation reaction. ESI-
TOF-MS m/z calcd for C78H82ClN26O14 [M + H]+ 1641.62; found 
1641.64. 
 
8.3 Cloning of 209 bp DNA fragments. 
All DNA fragments and primers for cloning or DNA amplification 
were purchased from SIGMA genosys. The 32 bp DNA fragment 
(ODN1: 5’-AAGCAGTCAAAAACCGGAAAGCAGTCTTTTT-
A-3’, and 5’-AAAAAGACTGCTTTCCGGTTTTTGACTGCT-
TA-3’) were ligated into pGEM–T Easy vectors (Promega), 
Escherichia coli DH5α competent cells (Toyobo) were 
transformed and cultured on LB plates with 100 µg/mL ampicillin 
and 32 µg X-gal /400 µg IPTG overnight at 37 °C. White colonies 
were identified by colony direct polymerase chain reaction (PCR) 
in 20 µL the reaction mixtures containing 250 nM of primer set 
(T7: 5’-TAATACGACTCACTATAGGG-3’, sp6: 5’-GATTTAG-
GTGACACTATAG-3’), 200 µM of deoxynucleotide 
triphosphates (Sigma Aldrich), 2 units Taq DNA polymerase and 
1 X ThermoPol Reaction Buffer (New England Bio Labs). The 
reaction mix was incubated at 95 °C for 5 min then followed by 
30 incubation cycles of 95 °C for 30 sec, 55 °C for 30 sec, and 
72 °C for 30 sec with final extension step of 72 °C for 7 min. The 
appropriate colony was selected for transfer to 5 mL of LB 
medium with 100 µg/mL ampicillin and cultured overnight at 
37 °C. The plasmids with inserts were extracted using GenEluteTM 
Plasmid Miniprep Kit (Sigma Aldrich) and identified by PCR. 
(program and reaction mixtures were the same as above) 
 
8.4 Preparation of 5’–Texas Red–labeled DNA Fragments and 
High Resolution Gel Electrophoresis. 
The 5'-Texas Red-modified 209 bp DNA fragment was prepared 
by PCR with 5’-TexasRed-modified sp6 and T7 primers from 1 
ng/µL of the 32 bp fragments inserted pGEM-T Easy vector 
(program and reaction mixtures were the same as above). 
Fragments were purified by GenEluteTM PCR Clean-up Kit 
(Sigma Aldrich), and their concentrations were determined by UV 
absorption. 
 
8.5 High-Resolution Gel Electrophoresis. 
The 5’-Texas Red-labeled DNA fragments (10 nM) were 
alkylated by various concentration of conjugates 1-5 in 10 µL of 5 
mM sodium phosphate buffer (pH 7.0) containing 10% DMF at 
23 °C. After incubation for 18 h, the reaction was quenched by the 
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addition of 10 µg of calf thymus DNA and heating for 10 min at 
95 ˚C. The solution was concentrated by vacuum centrifugation. 
The pellet was dissolved in 7 µL loading dye (formamide with 
fuschin red), heated at 95 ˚C for 25 min, and then immediately 
cooled to 0 ˚C. A 2 µL aliquot was subjected to electrophoresis on 
a 6% denaturing polyacrylamide gel using a Hitachi DNA 
Sequencers. 
 
8.6 Analysis of inhibition of the growth of the human K562 cell 
line. 
Detailed assay procedures were reported previously25. The human 
lymphocyte K562 cells were cultured in RPMI-1640 medium 
supplemented with 10% heat-inactivated fetal bovine serum, 
penicillin (100 IU/mL), and streptomycin (100 µg/mL) at 37 °C in 
a humidified atmosphere of 95% air and 5% CO2. Colorimetric 
assays with the WST-8 (Dojindo, Kumamoto, Japan) were carried 
out in 96-well plates. In the logarithmic growth phase, 5 × 103 
cells were plated into each well in 50 µL of culture medium. Then, 
medium (50 µL) containing various concentrations of compounds 
1–5 or 1% DMSO (50 µL) as a control was added to the wells. 
After treatment with the compounds for 48 h, WST-8 reagent (10 
µL) was added to each well, and the cells were incubated for 3 h 
at 37 °C. Absorbance was measured at 450 and 600 nm using an 
MPR-A4I microplate reader (Tosoh). The absorbances of the 
control (C), treated wells (T) and treated wells at time 0 (t0) were 
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